Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Ziopharm Oncology Announces Publication of Positive Results of Phase 1 Monotherapy Trial of Controlled IL-12 in Patients with Recurrent Glioblastoma in Science Translational Medicine
– Ad-RTS-hIL-12 plus 20 mg veledimex (Controlled IL-12 platform) determined to be the preferred dose with low-dose steroids to treat adult patients with recurrent glioblastoma – – Median overall survival for Controlled IL-12 in patients receiving low-dose steroids was 17.8 months – – Increased
View HTML
Toggle Summary Ziopharm Oncology Reports Second Quarter 2019 Financial Results
– FDA Cleared IND for Phase 1 Trial of Sleeping Beauty TCR-T cell therapy for  patients with solid tumors at the National Cancer Institute (NCI) – – Exclusive license from NCI for library of T-cell receptors (TCRs) targeting neoantigens in the hotspots KRAS, p53 and EGFR – – Balance sheet
View HTML
Toggle Summary Ziopharm Oncology Receives Positive Opinion for Orphan Drug Designation from the European Medicines Agency for Ad-RTS-hIL-12 plus Veledimex for the Treatment of Glioma
BOSTON , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) adopted a positive opinion recommending Ad-RTS-hIL-12 plus veledimex (Controlled
View HTML
Toggle Summary Ziopharm Oncology to Host Conference Call to Discuss Second Quarter 2019 Results on August 8, 2019
BOSTON , July 30, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast on Thursday, August 8 , at 8:30 a.m. ET to provide a corporate update and discuss financial results for the second quarter ended June 30 , 2019. 
View HTML
Toggle Summary Ziopharm Oncology Announces $45 Million Warrant Exercise by Existing Shareholders in a Private Placement
Provides capital to fund operations into 2021; warrant exercise in advance of November 2023 expiration BOSTON , July 29, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm”) (Nasdaq: ZIOP), today announced that it has entered into an agreement with existing investors for the exercise of
View HTML
Toggle Summary Ziopharm Oncology Names Sath Shukla as Chief Financial Officer
Joins from Vertex Pharmaceuticals; Served as global Head of Corporate Finance BOSTON , July 24, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP), a clinical stage immuno-oncology company developing next-generation cell and gene therapies, today announced
View HTML
Toggle Summary Ziopharm Oncology Names NCI’s Dr. Drew Deniger to Direct TCR-T Cell Therapy Program
– Dr. Deniger joins from National Cancer Institute to lead Ziopharm’s non-viral T-cell program targeting neoantigens for personalized immunotherapy of solid tumors – BOSTON , July 03, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP), today announced Drew
View HTML
Toggle Summary Ziopharm Oncology Initiates Phase 2 Trial Evaluating Combination Therapy of Controlled IL-12 with Libtayo® (cemiplimab-rwlc) to Treat Patients with Recurrent Glioblastoma
Phase 2 trial will enroll approximately 30 patients and evaluate both safety and efficacy BOSTON , June 27, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced the initiation of a phase 2 clinical trial evaluating Controlled IL-12
View HTML
Toggle Summary Ziopharm Oncology Completes Enrollment of Controlled IL-12 plus Opdivo® (nivolumab) Phase 1 Combination Trial in Brain Cancer
– Enrollment completed in third cohort of dose-escalation study at leading brain cancer hospitals in US; Investigators indicate interest in expanding study – BOSTON , June 26, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced completion of
View HTML
Toggle Summary Ziopharm Oncology Appoints Heidi Hagen to Board of Directors
Operations Management Leader for Immunex, Dendreon; Co-Founder and Chief Strategy Officer of Vineti BOSTON , June 17, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP), today announced Heidi Hagen , an experienced and entrepreneurial biotechnology
View HTML